Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

Astrazeneca Plc(AZN US)

$171.49-1.080.63%Ext:$169.17-2.321.35%(Market Closed · 00:00:04 UTC)

Overview

ProfileEntity Structure

Documents

SEC Filings
CategorizedChronologicalBy Owner

Financials & Metrics

FinancialsChartingShort InterestEmployees
Logo
AZN US​

SEC Filings

Financials(25)

Expand
  • 20-FFY 2025ended 31 Dec 202524 Feb
  • 20-FFY 2024ended 31 Dec 202418 Feb 2025
  • 20-FFY 2023ended 31 Dec 202320 Feb 2024
  • 20-FFY 2022ended 31 Dec 202221 Feb 2023
  • 20-FFY 2021ended 31 Dec 202122 Feb 2022
  • 20-FFY 2020ended 31 Dec 202016 Feb 2021
  • 20-FFY 2019ended 31 Dec 20193 Mar 2020
  • 20-FFY 2018ended 31 Dec 20185 Mar 2019
  • 20-FFY 2017ended 31 Dec 20176 Mar 2018
  • 20-FFY 2016ended 31 Dec 20167 Mar 2017
  • 20-FFY 2015ended 31 Dec 20158 Mar 2016
  • 20-FFY 2014ended 31 Dec 201410 Mar 2015
  • 20-FFY 2013ended 31 Dec 201320 Mar 2014
  • 20-FFY 2012ended 31 Dec 201225 Mar 2013
  • 20-F/AFY 2011ended 31 Dec 201121 Sep 2012

Events(1.6K)

Expand
  • 6-KULTOMIRIS APPROVED IN US IN IGAN22 Oct
  • 6-KASTRAZENECA COMPLETES EQUITY INVESTMENT IN SUMMIT5 Oct
  • 6-KAZ & DS COLLABORATION WITH SUMMIT FOR DATROWAY2 Oct
  • 6-KADMISSION OF FURTHER SECURITIES TO TRADING1 Oct
  • 6-KTOTAL VOTING RIGHTS1 Oct
  • 6-KASTRAZENECA ANNOUNCES EQUITY INVESTMENT IN SUMMIT29 Sep
  • 6-KTRIXEO APPROVED IN EU FOR ASTHMA23 Sep
  • 6-KKLYGEFA RECOMMENDED FOR EU APPROVAL BY CHMP21 Sep
  • 6-KENHERTU RECOMMENDED FOR APPROVAL IN EU IN EARLY BC21 Sep
  • 6-KDIRECTOR/PDMR SHAREHOLDING18 Sep
  • 6-KDIRECTOR/PDMR SHAREHOLDING15 Sep
  • 6-KDIRECTOR/PDMR SHAREHOLDING15 Sep
  • 6-KUPDATE ON SERENA-4 PHASE III TRIAL14 Sep
  • 6-KIMFINZI+IMDELLTRA IMPROVED OS IN SMALL CELL LUNG8 Sep
  • 6-KETCAMAH APPROVED IN THE US FOR HR+ BREAST CANCER8 Sep

Insider Ownership(23)

Expand
  • 4Sharma Mani8 Oct
  • 4Sharma Mani11 Sep
  • 4Sharma Mani7 Aug
  • 4Sharma Mani8 Jul
  • 4Sharma Mani16 Jun
  • 4Sharma Mani22 May
  • 4Sharma Mani8 May
  • 3Sharma Mani19 Mar
  • 4Statement of changes in beneficial ownership16 Mar 2021
  • 4Statement of changes in beneficial ownership7 Feb 2020
  • 3Initial statement of beneficial ownership7 Feb 2020
  • 3/AInitial statement of beneficial ownership (amendment)9 Oct 2019
  • 4Statement of changes in beneficial ownership9 Oct 2019
  • 3Initial statement of beneficial ownership2 Oct 2019
  • 4Statement of changes in beneficial ownership24 Oct 2018

Beneficial Ownership(81)

Expand
  • SC 13GASTRAZENECA PLC28 Apr
  • SC 13G/AMonopar Therapeutics6 Feb
  • SC 13D/AInnate Pharma SA6 Feb
  • SC 13G/AASTRAZENECA PLC23 Apr 2025
  • SC 13G/ACONDUIT PHARMACEUTICALS INC.10 Apr 2025
  • SC 13D/ACellectis S.A.24 Jan 2025
  • SC 13GMonopar Therapeutics28 Oct 2024
  • SC 13GCONDUIT PHARMACEUTICALS INC.11 Oct 2024
  • SC 13G/AADC Therapeutics SA12 Feb 2024
  • SC 13G/AASTRAZENECA PLC24 Jan 2024
  • SC 13D/ACellectis S.A.16 Nov 2023
  • SC 13DCellectis S.A.9 Nov 2023
  • SC 13G/APIERIS PHARMACEUTICALS, INC.10 Feb 2023
  • SC 13G/AAridis Pharmaceuticals, Inc.10 Feb 2023
  • SC 13G/AASTRAZENECA PLC24 Jan 2023

Other Ownership(26)

Expand
  • 11-KAnnual report (employee stock purchase/savings/profit sharing plans)29 Jun
  • 144SARIN ARADHANA12 Nov 2025
  • 11-KAnnual report (employee stock purchase/savings/profit sharing plans)26 Jun 2025
  • 11-KANNUAL REPORT26 Jun 2024
  • 144SARIN ARADHANA13 Nov 2023
  • 11-KANNUAL REPORT28 Jun 2023
  • 11-KANNUAL REPORT29 Jun 2022
  • 11-KAnnual report (employee stock purchase/savings/profit sharing plans)29 Jun 2021
  • 11-KAnnual report (employee stock purchase/savings/profit sharing plans)26 Jun 2020
  • 11-KAnnual report (employee stock purchase/savings/profit sharing plans)27 Jun 2019
  • 11-KAnnual report (employee stock purchase/savings/profit sharing plans)29 Jun 2018
  • 11-KAUTO-GENERATED PAPER DOCUMENT29 Jun 2017
  • 11-KAUTO-GENERATED PAPER DOCUMENT28 Jun 2016
  • 11-KAUTO-GENERATED PAPER DOCUMENT26 Jun 2015
  • 11-KAUTO-GENERATED PAPER DOCUMENT24 Jun 2014

Proxies(1)

Expand
  • DFAN14ADefinitive additional soliciting materials19 Mar 2024

Registrations(157)

Expand
  • 25-NSENotification of removal from listing28 May
  • 25-NSENotification of removal from listing8 Apr
  • 8-A12BRegistration of securities (Section 12(b))3 Mar
  • 424B2Prospectus filing (Rule 424(b)(2))27 Feb
  • FWPFree writing prospectus25 Feb
  • 424B2Prospectus filing (Rule 424(b)(2))25 Feb
  • S-8Registration statement (employee benefit plan)3 Feb
  • 8-A12BRegistration of securities (Section 12(b))22 Jan
  • 8-A12BRegistration of securities (Section 12(b))22 Jan
  • 25-NSENotification of removal from listing14 Nov 2025
  • F-6Registration statement (depository shares)21 Jan 2025
  • 25-NSENotification of removal from listing4 Jun 2024
  • F-3ASRAutomatic shelf registration statement (F-3)19 Mar 2024
  • 8-A12BRegistration of securities (Section 12(b))5 Mar 2024
  • 424B2Prospectus filing (Rule 424(b)(2))23 Feb 2024

Filing Review Correspondence(11)

Expand
  • CORRESPFiling review correspondence10 Jan 2024
  • CORRESPFiling review correspondence8 Apr 2021
  • CORRESPFiling review correspondence29 Nov 2010
  • UPLOADFiling review upload15 Nov 2010
  • UPLOADFiling review upload10 Nov 2010
  • CORRESPFiling review correspondence28 Oct 2010
  • CORRESPFiling review correspondence30 Sep 2010
  • CORRESPFiling review correspondence20 May 2008
  • CORRESPFiling review correspondence7 May 2008
  • CORRESPFiling review correspondence21 Jun 2006
  • CORRESPFiling review correspondence15 Jun 2006

SEC Orders And Notices(6)

Expand
  • EFFECTNotice of effectiveness5 Feb 2025
  • EFFECTNotice of effectiveness12 Apr 2021
  • EFFECTNotice of effectiveness6 Feb 2020
  • EFFECTNotice of effectiveness5 Dec 2014
  • CT ORDERConfidential treatment order14 Apr 2014
  • CT ORDERConfidential treatment order25 Oct 2012

Tender Offers And Going Private(25)

Expand
  • SC TO-T/ATender offer statement (third-party, amendment)21 Feb 2024
  • SC TO-T/ATender offer statement (third-party, amendment)20 Feb 2024
  • SC TO-T/ATender offer statement (third-party, amendment)15 Feb 2024
  • SC TO-T/ATender offer statement (third-party, amendment)19 Jan 2024
  • SC TO-T/ATender offer statement (third-party, amendment)11 Jan 2024
  • SC TO-TTender offer statement (third-party)27 Dec 2023
  • SC TO-CTender offer statement (communication)12 Dec 2023
  • SC TO-T/ATender offer statement (third-party, amendment)24 Feb 2023
  • SC TO-T/ASC TO-T23 Feb 2023
  • SC TO-T/ATender offer statement (third-party, amendment)3 Feb 2023
  • SC TO-TTender offer statement (third-party)23 Jan 2023
  • SC TO-CTender offer statement (communication)9 Jan 2023
  • SC TO-T/AAMENDMENT NO. 12 TO SCHEDULE TO22 Aug 2006
  • SC TO-T/AAMENDMENT NO. 11 TO SCHEDULE TO7 Jul 2006
  • SC TO-T/ASCHEDUEL TO-T AMENDMENT NO.1030 Jun 2006

Other(32)

Expand
  • CERTCERT4 Mar
  • IRANNOTICEIRANNOTICE24 Feb
  • 252530 Jan
  • CERTCERT22 Jan
  • CERTCERT22 Jan
  • IRANNOTICEIRANNOTICE18 Feb 2025
  • CERTCERT6 Mar 2024
  • IRANNOTICEIRANNOTICE20 Feb 2024
  • CERTCERT15 Mar 2023
  • IRANNOTICEIRANNOTICE21 Feb 2023
  • IRANNOTICEIRANNOTICE22 Feb 2022
  • CERTCERT3 Jun 2021
  • IRANNOTICEIRANNOTICE16 Feb 2021
  • CERTCERT24 Sep 2020
  • 252524 Sep 2020